EAM
Exome Asset Management Portfolio holdings
AUM
$151M
1-Year Est. Return
46.2%
1 Year Est. Return
+46.2%
AUM
$151M
AUM Growth
+$41.1M
(+37%)
Holding
85
Top Buys
| 1 | +$5.44M | |
| 2 | +$4.27M | |
| 3 | +$3.75M | |
| 4 |
Arrowhead Research
ARWR
|
+$3.6M |
| 5 |
CVS Health
CVS
|
+$3.29M |
Top Sells
| 1 | +$3.18M | |
| 2 | +$2.99M | |
| 3 | +$2.93M | |
| 4 |
Verastem
VSTM
|
+$2.49M |
| 5 |
Geron
GERN
|
+$2.13M |
Sector Composition
| 1 | Healthcare | 97.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Ultragenyx Pharmaceutical
RARE
$2.18B
| – | – |
0
|
|
||
77
Regenxbio
RGNX
$714M
| – | – |
-226,060
|
|
||
78
Scholar Rock
SRRK
$4.56B
| – | – |
-84,339
|
|
||
79
Instil Bio
TIL
$48M
| – | – |
-16,200
|
|
||
80
UnitedHealth
UNH
$307B
| – | – |
0
|
|
||
|
81
Verastem
VSTM
$501M
| – | – |
-599,900
|
|
||
82
VYNE Therapeutics
VYNE
$19.1M
| – | – |
-208,970
|
|
||
|
ATYR
83
aTyr Pharma
ATYR
$69.2M
| – | – |
0
|
|